Last mentioned: Mar 18, 2026
PDUFA Date
Target date for FDA decision on INO-3107 accelerated approval.
Platform Modernization
LivePerson expects to complete its multiyear platform modernization.
BLA Acceptance
FDA accepts Inovio's BLA for INO-3107 under accelerated approval program.
Inovio Cash Position
Company ends the year with $94.1 million in cash.
LivePerson, Inovio, and Bakkt reported Q4 2025 results highlighting strategic transitions toward AI integration, regulatory milestones, and balance sheet restructuring. While LivePerson capitalizes on generative AI adoption and Inovio nears a critical FDA PDUFA date, Bakkt has streamlined its capital structure to focus on institutional crypto services.
Inovio Pharmaceuticals faces a critical regulatory juncture as the FDA accepts its BLA for INO-3107 while questioning its accelerated approval eligibility. Meanwhile, LivePerson is pivoting toward a unified AI architecture with the launch of its Syntrix platform, signaling a shift in how healthcare enterprises may manage patient engagement.